These open issues led us to study about whether MET activation under hypoxia inducing a tumor-invasive switch in HCC is a mechanism of refractory to antiangiogenic treatment and whether this form of evasive resistance can be prevented or reversed by inhibition of MET in HCC. The gene discussed is MET; the disease is neoplasm.